Adjuvant chemoradiation therapy in gallbladder cancer

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Surgical Oncology

Background:

• Gallbladder cancer is a rare gastrointestinal malignancy.
• Optimal adjuvant therapy post-surgical resection remains undetermined.
• TNM staging is crucial for treatment decisions.

Purpose of the Study:

• To evaluate the effectiveness of adjuvant chemoradiation therapy (CRT) in gallbladder cancer.
• To determine the impact of CRT based on TNM stage.
• To identify prognostic factors influencing survival after resection.

Main Methods:

• Retrospective analysis of 100 patients with gallbladder cancer undergoing surgical resection (2001-2009).
• Patients stratified by TNM stage (T2N0M0, T2N1M0, T3N0M0, T3N1M0).
• Comparison of outcomes between patients who received adjuvant CRT and those who did not.

Main Results:

• Adjuvant CRT did not improve survival in lymph node-negative stages (T2N0M0, T3N0M0).
• Lymph node-positive stages (T2N1M0, T3N1M0) demonstrated improved disease-free survival with CRT.
• Adjuvant CRT was an independent prognostic factor for survival in lymph node-positive T2/T3 gallbladder cancer.

Conclusions:

• Adjuvant chemoradiation therapy is recommended for lymph node-positive (T2N1M0, T3N1M0) gallbladder cancer post-surgical resection.
• The study highlights the importance of nodal status in guiding adjuvant treatment decisions.
• Further research may refine indications for CRT in specific gallbladder cancer subgroups.